• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHAO Jianing,MA Tingting,KUANG Xiaoqin,HAO Mingyu,LI Chunjiayu,TU Jiasheng,SUN Chunmeng,WU Yanping,CHEN Qian.Research advances on cellular membrane nanovesicles for tumor vaccines[J].Journal Of Pharmaceutical Research,2025,44(2):155-164[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2678times   Download 1328次 QR Code for this article
Scan with your phone!
细胞膜纳米囊泡用于肿瘤疫苗的研究进展
赵佳凝1,2,3,马婷婷1,2,3,况小勤1,2,3,郝茗羽1,2,3,李春佳雨1,2,3,涂家生1,2,3,孙春萌1,2,3,吴彦萍1,4,陈芊1,5
Font:Larger+|Default|Smaller-
(1.中国药科大学多靶标天然药物全国重点实验室,江苏 南京 211198;2.中国药科大学药学院药剂系,江苏 南京 211198;3.国家药品监督管理局药物制剂及辅料研究与评价重点实验室,江苏 南京 210009;4.中国药科大学基础医学与临床药学学院,江苏 南京 211198;5.江苏省药物代谢动力学重点实验室,江苏 南京 210009)
摘要:
近年来肿瘤免疫治疗取得了突破性进展。肿瘤疫苗通过增强免疫原性,克服免疫抑制,从而激活自身免疫识别并杀灭肿瘤细胞,是一种极具前景的免疫疗法。仿生型细胞膜纳米囊泡具有肿瘤特异性靶向、延长体内半衰期以及免疫激活效果等优势,为肿瘤疫苗的设计开辟了新思路。本文综述了近年细胞膜纳米囊泡在肿瘤疫苗方面的研究进展,总结了细胞膜纳米囊泡的特点、制备与表征方法和修饰手段,并对细胞膜纳米囊泡在临床应用中面临的挑战进行分析。
关键词:  肿瘤免疫治疗  肿瘤疫苗  细胞膜纳米囊泡  药物递送系统
DOI:10.13506/j.cnki.jpr.2025.02.010
基金项目:国家自然科学基金青年项目(No.82303820)
Publication Date:February 25, 2025
Research advances on cellular membrane nanovesicles for tumor vaccines
ZHAO Jianing1,2,3,MA Tingting1,2,3,KUANG Xiaoqin1,2,3,HAO Mingyu1,2,3,LI Chunjiayu1,2,3,TU Jiasheng1,2,3,SUN Chunmeng1,2,3,WU Yanping1,4,CHEN Qian1,5
(1.State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, China;2.Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China;3.NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, China Pharmaceutical University, Nanjing 210009, China;4.Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, Nanjing 210009, China;5.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China)
Abstract:
In recent years, breakthroughs have been made in tumor immunotherapy. Tumor vaccines can overcome immunosuppression by enhancing immunogenicity, thereby activating immunity to recognize and kill tumor cells, which is a promising immunotherapy modality. Biomimetic cellular membrane nanovesicles with the advantages of tumor specific targeting, prolonged half-life and immune activation effects have potential to flourish the design of tumor vaccines. In this review, we summarized the recent progresses of various cellular membrane nanovesicles in the application of tumor vaccines, discussed their characteristics, preparation, characterization and modification methods, and analyzed the challenges in clinical application.
Key words:  Tumor immunotherapy  Tumor vaccines  Cellular membrane nanovesicles  Drug delivery system
Today's Visits:487    Total Visits:2383201
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.